The startup has developed a fast-gelling injectable hydrogel composed of hyaluronan and methylcellulose, which liquefies under force to enable localized and sustained drug delivery. This technology aims to reduce post-operative pain for patients across various therapeutic areas by providing targeted medication release.
Funding
$15.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Post-operative pain management often relies on systemic medications, leading to potential side effects and incomplete pain relief. Current methods may not effectively target the pain source, resulting in inadequate analgesia and prolonged recovery times for patients undergoing surgical procedures.
Solution
AmacaThera has developed an injectable hydrogel platform, AmacaGel, designed for localized and sustained drug delivery. This shear-thinning hydrogel liquefies under force, allowing for precise injection into the target site, and then reforms to provide a controlled-release depot of medication. By delivering therapeutics directly to the affected area, AmacaThera aims to reduce the need for systemic analgesics, minimize side effects, and improve patient outcomes across various therapeutic areas, with an initial focus on post-operative pain management using their lead asset, AMT-143. The hydrogel is composed of hyaluronan and methylcellulose.
Target Audience
The primary target audience includes surgeons, anesthesiologists, and pain management specialists seeking improved post-operative pain control, as well as hospitals and clinics looking to enhance patient recovery and reduce reliance on systemic opioids.
Features
- Injectable hydrogel that provides localized and sustained drug delivery
- Shear-thinning properties enable easy injection and precise placement
- Biocompatible and biodegradable materials (hyaluronan and methylcellulose)
- Controlled-release mechanism for prolonged therapeutic effect
- AMT-143, a non-opioid formulation for acute pain management, is the lead asset
- Potential applications in post-surgical pain, cancer, and other hard-to-reach target areas